EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce

Julijana Asllani iD, Dimitrios Mitsias, George Konstantinou iD, Eris Mesonjesi, Fatmira Xhixha, Esmeralda Shehu, George Christoff, Katia Noleva, Michael Makris, Xenofon Aggelidis iD, Mirjana Turkalj, Erceg Damir und 9 weitere

Clinical and Translational Allergy · 2023-06 · 13 (6)

DOI: 10.1002/clt2.12250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 02.06.2023. Verfasst von Julijana Asllani und 20 weiteren Autor:innen. Beteiligte Einrichtung: University of Medicine, Tirana, Albania. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stallergenes, European Academy of Allergy and Clinical Immunology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although it has been shown that allergen immunotherapy (AIT) is well‐tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed.

Methods

The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to address AIT safety in real life clinical practice. Data on children ≤18 years old with respiratory allergies undergoing AIT were retrieved. Patient‐ and AIT‐related features were collected and analyzed. The characteristics of adverse events (AE) and risk factors were evaluated.

Results

A total of 851 patients, 11.3 ± 3.4 years old, with rhinitis only (47.6%); asthma and rhinitis (44.5%); asthma (7.9%), receiving 998 AIT courses were analyzed. Sublingual immunotherapy (SLIT) accounted for 51% of the courses. In 84.5% of patients only one AIT treatment was prescribed. Pollen was the most frequent sensitizer (57.1%), followed by mites (53.4%), molds (18.2%) and epithelia (16.7%). Local and systemic AEs were reported in 85 patients (9.9%). Most AEs (83.1%) were mild and occurred in

Schlagwörter

Stichwörter der Autor:innen

adverse eventsallergen immunotherapyreal-life settingsrisk factors

Autor:innen und Institutionen

  • University of Medicine, Tirana, Albania.
  • Allergy and Asthma Medical Clinic, Tirana, Albania.
  • Allergy Department 2nd Pediatric Clinic, University of Athens, Athens, Greece.
  • Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.
  • University Hospital Center "Mother Teresa", Tirana, Albania.
  • Ambulatory Polyclinic of Specialties, Nr. 3, Tirana, Albania.

ORCID-Profile: Julijana Asllani, George Konstantinou, Xenofon Aggelidis

Förderung

  • Stallergenes
  • European Academy of Allergy and Clinical Immunology

Zitieren

APA

Asllani, J., Mitsias, D., Konstantinou, G., Mesonjesi, E., Xhixha, F., Shehu, E., Christoff, G., Noleva, K., Makris, M., Aggelidis, X., Turkalj, M., Damir, E., Agache, I., Tomic-Spiric, V., Stosovic, R., Misirligil, Z., Kosnik, M., Popov, T. A., Calderon, M., …, & ADER study group (2023). Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce. Clinical and Translational Allergy, 13(6). https://doi.org/10.1002/clt2.12250

Vancouver

Asllani J, Mitsias D, Konstantinou G, Mesonjesi E, Xhixha F, Shehu E, et al. Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce. Clinical and Translational Allergy. 2023;13(6). doi:10.1002/clt2.12250

BibTeX
@article{Asllani2023,
  author = {Asllani, Julijana and Mitsias, Dimitrios and Konstantinou, George and Mesonjesi, Eris and Xhixha, Fatmira and Shehu, Esmeralda and Christoff, George and Noleva, Katia and Makris, Michael and Aggelidis, Xenofon and Turkalj, Mirjana and Damir, Erceg and Agache, Ioana and Tomic-Spiric, Vesna and Stosovic, Rajica and Misirligil, Zeynep and Kosnik, Mitja and Popov, Todor A and Calderon, Moises and Papadopoulos, Nikolaos G and ADER study group, ADER study group},
  title = {Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce},
  journal = {Clinical and Translational Allergy},
  year = {2023},
  volume = {13},
  number = {6},
  doi = {10.1002/clt2.12250}
}
Kostenlos starten →